These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31595429)

  • 1. Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.
    Saqlain M; Alam M; Rönnegård L; Westin J
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):41-49. PubMed ID: 31595429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA; Dutta S
    Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
    Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
    Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
    Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
    J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
    Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
    Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
    Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment.
    Miyaue N; Hosokawa Y; Yoshida A; Yamanishi Y; Tada S; Ando R; Yabe H; Nagai M
    Parkinsonism Relat Disord; 2021 Oct; 91():55-58. PubMed ID: 34509136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
    Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T
    Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.